Lopez-de la Mora David Alejandro, Sanchez-Roque Cibeles, Montoya-Buelna Margarita, Sanchez-Enriquez Sergio, Lucano-Landeros Silvia, Macias-Barragan Jose, Armendariz-Borunda Juan
1. Institute for Molecular Biology and Gene Therapy, Department of Molecular Biology and Genomics, University of Guadalajara, Sierra Mojada St. 950, Guadalajara (44280), Mexico.
1. Institute for Molecular Biology and Gene Therapy, Department of Molecular Biology and Genomics, University of Guadalajara, Sierra Mojada St. 950, Guadalajara (44280), Mexico. ; 2. Departamento de Ciencias de la Salud, CUValles, University of Guadalajara, Guadalajara - Ameca km. 45.5, Ameca (46600), Mexico.
Int J Med Sci. 2015 Oct 14;12(11):840-7. doi: 10.7150/ijms.11579. eCollection 2015.
Pirfenidone (PFD) is a non-peptide synthetic molecule issued as a broad-spectrum anti-fibrotic drug with the ability to decrease TGF-β1, TNF-α, PDGF and COL1A1 expression, which is highly related to prevent or remove excessive deposition of scar tissue in several organs. Basic and clinical evidence suggests that PFD may safely slow or inhibit the progressive fibrosis swelling after tissue injuries. Furthermore, a number of evidence suggests that this molecule will have positive effects in the treatment of other inflammatory diseases. This review contains current research in which PFD has been used as the treatment of several diseases, and focus mainly in the outcomes related to improve inflammation and fibrogenesis. Therefore, the main goal of this review is to focus on the novel findings of PFD efficacy rather than deepen in the chemical aspects of the molecule.
吡非尼酮（PFD）是一种非肽类合成分子，作为一种广谱抗纤维化药物，能够降低与预防或消除多个器官中瘢痕组织过度沉积高度相关的转化生长因子-β1（TGF-β1）、肿瘤坏死因子-α（TNF-α）、血小板衍生生长因子（PDGF）和I型胶原蛋白α1（COL1A1）的表达。基础和临床证据表明，PFD可能安全地减缓或抑制组织损伤后进行性纤维化肿胀。此外，大量证据表明该分子在治疗其他炎症性疾病方面将产生积极作用。本综述涵盖了目前将PFD用于治疗多种疾病的研究，主要关注与改善炎症和纤维化形成相关的结果。因此，本综述的主要目标是聚焦于PFD疗效的新发现，而非深入探讨该分子的化学方面。
